607 results on '"Geisbert, Thomas W."'
Search Results
2. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus
3. Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection
4. Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects
5. Nonhuman Primate Models for Nipah and Hendra Virus Countermeasure Evaluation
6. Overview of Experimental Vaccines and Antiviral Therapeutics for Henipavirus Infection
7. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates
8. Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
9. A Glass-Half-Full Perspective on Negative Data in Ebolavirus Vaccine Studies
10. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus
11. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates
12. Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein
13. Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease
14. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins
15. Establishment of an African green monkey model for COVID-19 and protection against re-infection
16. Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever
17. High-Avidity Anti-Filovirus IgG Elicited Using Protein Subunit Vaccines Does Not Correlate with Protection
18. Revisiting the minimum incubation period of Zaire ebolavirus
19. Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret ( Mustela putorius furo )
20. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates
21. Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans
22. Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms
23. Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
24. Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
25. Combination therapy protects macaques against advanced Marburg virus disease
26. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
27. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death
28. Marburg and Ravn Viruses (Filoviridae)
29. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections
30. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
31. Antibody therapy for Lassa fever
32. Animal Models for Henipavirus Research
33. Modelling Marburg Virus Disease in Syrian Golden Hamsters: Contrasted Virulence between Angola and Ci67 strains
34. Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting
35. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus
36. Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection
37. Limited benefit of post-exposure prophylaxis with VSV-EBOV in Ebola virus-infected rhesus macaques
38. Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody
39. Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
40. Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona
41. A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus
42. Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates
43. An Outbreak of Ebola Virus Disease in the Lassa Fever Zone
44. Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus
45. Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus Directly From Blood
46. Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates
47. Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection
48. Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection
49. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop
50. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.